Skip Navigation



Rheumatology Advance Access published online on October 25, 2009
Rheumatology, doi:10.1093/rheumatology/kep330
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lynch, M.
Right arrow Articles by Kirby, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lynch, M.
Right arrow Articles by Kirby, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate

Maeve Lynch1 and Brian Kirby1

1Department of Dermatology, St Vincents University Hospital, Dublin, Ireland.

Correspondence to: Maeve Lynch, Department of Dermatology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland. E-mail: lynchmaeve@yahoo.ie

The first 10% of the full text of this article appears below.

SIR, We read with interest the recent article by Amital et al. [1] that compared hepatotoxicity rates in PsA and RA patients treated with MTX based on the evaluation of standard liver function tests. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?